Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

NCT05613114 is registered in ClinicalTrials.gov with European University of Lefke as lead sponsor.

NCT NCT05613114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05613114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia
Lead sponsor
European University of Lefke
Phase
Not applicable
Overall status
Completed
Start date
August 3, 2020
Completion date
March 12, 2021
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary spastic paraplegia